Key result
Concomitant perindopril and atorvastatin therapy significantly reduced mean systolic blood pressure by 18.0 mmHg and diastolic blood pressure by 8.9 mmHg from baseline.
Why the study?
Optimal blood pressure and lipid targets remain inadequately achieved in clinical practice despite their importance in cardiovascular risk management.
Does the free combination of perindopril and atorvastatin reduce blood pressure in mild-to-moderate hypertensive patients with dyslipidemia?
Observational (n=3,172)
Yes
Does the free combination of perindopril and atorvastatin reduce blood pressure in mild-to-moderate hypertensive patients with dyslipidemia?
Answers are grounded in this paper and cite their sources.
Concomitant perindopril and atorvastatin therapy effectively reduces blood pressure and is well-tolerated in real-world patients with mild-to-moderate hypertension and dyslipidemia.
BACKGROUND AND OBJECTIVES: Management of hypertension and dyslipidemia is important when considering cardiovascular disease risk; however, achievement of optimal lipid and blood pressure (BP) targets in clinical practice remains inadequate. This analysis sought to estimate the frequency, effectiveness, and safety of co-administrated atorvastatin and perindopril in routine care. METHODS: We conducted a post hoc analysis of four Canadian, prospective, multi-center, observational studies assessing real-life effectiveness and safety of perindopril + atorvastatin in mild-to-moderate hypertensive patients with concomitant dyslipidemia over 16 weeks. The safety population comprised patients receiving one or more doses of free combination perindopril + atorvastatin; the full analysis set (FAS) received perindopril + atorvastatin at baseline, with one or more post-baseline systolic BP measurements while on treatment. RESULTS: A total of 3541 and 3172 patients were included in the safety population and FAS, respectively. At the last observation carried forward, significant reductions in mean systolic BP (- 18.0 mmHg; p < 0.001) and diastolic BP (- 8.9 mmHg; p < 0.001) were observed; target BP was achieved by 73.1% of patients. Emergent adverse events (AEs) were reported in 8.0% of patients, the most common being cough (4.5% of patients), headache (0.9%), and dizziness (0.8%). Four serious AEs were reported among three (0.1%) patients. No differences were observed in effectiveness or safety between studies. CONCLUSIONS: Concomitant perindopril + atorvastatin therapy demonstrated similar efficacy across all studies, with significant reductions in BP and achievement of target BP levels observed in a real-world setting. Results align with known safety profiles of atorvastatin and perindopril, with no unexpected AEs observed when compared with data from treatment with the individual drugs.
No takes yet. Share an insight, caveat, or question.
Sampalis et al. (2018) conducted an observational in Mild to moderate hypertension with concomitant dyslipidemia (n=3,172). Perindopril and Atorvastatin vs. Baseline was evaluated on Change from baseline in mean systolic blood pressure at last observation carried forward (MD -18.0, p=<0.001). Concomitant perindopril and atorvastatin therapy significantly reduced mean systolic blood pressure by 18.0 mmHg and diastolic blood pressure by 8.9 mmHg from baseline.
Synapse has enriched 10 related papers. Consider them for comparative context: